Literature DB >> 1449179

Evaluation of perilymphatic fistulas by middle ear endoscopy.

D S Poe1, E E Rebeiz, M M Pankratov.   

Abstract

Transtympanic endoscopy provides a unique opportunity to view the undisturbed contents of the middle ear. Fiberoptic and rigid endoscopes have been used for thorough examination of the middle ear without the need for local anesthetics or surgical trauma. Endoscopy is now routinely used in the evaluation of a perilymphatic fistula and the patient is awake during an intermittent forceful Valsalva maneuver. Oval and round windows in both ears of five cats were studied endoscopically to evaluate surgically created fistulas. Excellent visualization of the defect was obtained in all instances. Endoscopy is a useful office technique for the evaluation of perilymphatic fistula. It reduces the need for surgical exploration and provides a satisfactory examination of the middle ear. Obliteration of the window niche can even be performed through the myringotomy using autologous blood.

Entities:  

Mesh:

Year:  1992        PMID: 1449179

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  5 in total

Review 1.  Perilymphatic fistula.

Authors:  C G Maitland
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  A minimally invasive technique for endoscopic middle ear surgery.

Authors:  B Fabinyi; C Klug
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

3.  Perilymph fistula: fifty years of controversy.

Authors:  Jeremy Hornibrook
Journal:  ISRN Otolaryngol       Date:  2012-07-31

4.  Low-frequency sound pressure and transtympanic endoscopy of the middle ear in assessment of "spontaneous" perilymphatic fistula.

Authors:  Ilmari Pyykkö; Ziane Selmani; Jing Zou
Journal:  ISRN Otolaryngol       Date:  2012-08-07

5.  Endoscopic Repair of Traumatic Perilymphatic Fistula in Children: A Case Series.

Authors:  Rounak Rawal; Xue Zhao; Sophie Lipson; Jacob R Brodsky
Journal:  J Int Adv Otol       Date:  2021-03       Impact factor: 1.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.